{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-018867","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.832766+00:00","generated_at":"2026-05-25T23:50:02.440151+00:00","sec_items":["1.01","5.02","5.08","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Onconetix appoints James Sapirstein as Executive Chairman; former Interim CEO resigns","bullets":["Dr. Ralph Schiess resigned as Interim CEO and CSO effective Feb 24, 2025; also to leave Proteomedix AG CEO role on May 31, 2025.","James Sapirstein, existing Board member, appointed Executive Chairman; he is also CEO of Entero Therapeutics (Nasdaq: ENTO).","Sapirstein compensated $400/hour for up to 20 hours/week; payment contingent on company securing sufficient capital.","Board expanded from five to six; Andrew Oakley appointed as Class II director; former CFO at Autolus, Sosei, Vectura, Actelion."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-018867","json":"https://secwatch.observer/filing/0001213900-25-018867.json","markdown":"https://secwatch.observer/filing/0001213900-25-018867.md","text":"https://secwatch.observer/filing/0001213900-25-018867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/ea0232572-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T23:50:02.440151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8409c7cea4","claim":"Andrew Oakley was appointed as Class II director at Onconetix, Inc..","evidence_excerpt":"On February 24, 2025, the Board approved an increase to the Board’s size from five to six members and appointed Andrew Oakley, 62, to fill the new Board seat as a Class II director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"},{"claim_id":"94076bf8cc","claim":"James Sapirstein was appointed as Executive Chairman at Onconetix, Inc..","evidence_excerpt":"On February 24, 2025, the Company’s Board of Directors (the “Board”) appointed James Sapirstein, 63, an existing member of the Board, as Executive Chairman.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"b14b1b6922","claim":"Ralph Schiess resigned as Interim Chief Executive Officer and Chief Science Officer at Onconetix, Inc..","evidence_excerpt":"On February 24, 2025, Dr. Ralph Schiess resigned from his positions as the Interim Chief Executive Officer and Chief Science Officer of Onconetix, Inc. (the “Company”), effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Chief Executive Officer and Chief Science Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}